
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023, AgeX and Juvenescence Limited entered into an…











